159 related articles for article (PubMed ID: 37878152)
1. Surgery of the primary tumor in patients with de novo metastatic breast cancer: a nationwide population-based retrospective cohort study in Belgium.
Brandão M; Martins-Branco D; De Angelis C; Vuylsteke P; Gelber RD; Van Damme N; van Walle L; Ferreira AR; Lambertini M; Poggio F; Verhoeven D; Barbeaux A; Duhoux FP; Wildiers H; Caballero C; Awada A; Piccart-Gebhart M; Punie K; de Azambuja E
Breast Cancer Res Treat; 2024 Jan; 203(2):351-363. PubMed ID: 37878152
[TBL] [Abstract][Full Text] [Related]
2. Clinical outcome in women with HER2-positive de novo or recurring stage IV breast cancer receiving trastuzumab-based therapy.
Rossi V; Nolè F; Redana S; Adamoli L; Martinello R; Aurilio G; Verri E; Sapino A; Viale G; Aglietta M; Montemurro F
Breast; 2014 Feb; 23(1):44-9. PubMed ID: 24210572
[TBL] [Abstract][Full Text] [Related]
3. Patterns of Care and Clinical Outcomes of HER2-positive Metastatic Breast Cancer Patients With Newly Diagnosed Stage IV or Recurrent Disease Undergoing First-line Trastuzumab-based Therapy: A Multicenter Retrospective Cohort Study.
Lambertini M; Ferreira AR; Di Meglio A; Poggio F; Puglisi F; Sottotetti F; Montemurro F; Poletto E; Bernardo A; Risi E; Dellepiane C; Sini V; Minuti G; Grasso D; Fancelli S; Del Mastro L
Clin Breast Cancer; 2017 Dec; 17(8):601-610.e2. PubMed ID: 28479052
[TBL] [Abstract][Full Text] [Related]
4. Prognostic Value of Site-Specific Metastases and Surgery in De Novo Stage IV Triple-Negative Breast Cancer: A Population-Based Analysis.
Gu Y; Wu G; Zou X; Huang P; Yi L
Med Sci Monit; 2020 Feb; 26():e920432. PubMed ID: 32043484
[TBL] [Abstract][Full Text] [Related]
5. Exploring the Value of Additional Primary Tumour Excision Combined with Systemic Therapy Administered in Different Sequences for Patients with de Novo Metastatic Breast Cancer.
Zhu S
Breast J; 2022; 2022():5049445. PubMed ID: 36082023
[TBL] [Abstract][Full Text] [Related]
6. Survival Impact of Locoregional Treatment of the Primary Tumor in De Novo Metastatic Breast Cancers in a Large Multicentric Cohort Study: A Propensity Score-Matched Analysis.
Pons-Tostivint E; Kirova Y; Lusque A; Campone M; Geffrelot J; Mazouni C; Mailliez A; Pasquier D; Madranges N; Firmin N; Crouzet A; Gonçalves A; Jankowski C; De La Motte Rouge T; Pouget N; de La Lande B; Mouttet-Boizat D; Ferrero JM; Uwer L; Eymard JC; Mouret-Reynier MA; Petit T; Robain M; Filleron T; Cailliot C; Dalenc F
Ann Surg Oncol; 2019 Feb; 26(2):356-365. PubMed ID: 30539492
[TBL] [Abstract][Full Text] [Related]
7. Survival with metastatic breast cancer based on initial presentation, de novo versus relapsed.
den Brok WD; Speers CH; Gondara L; Baxter E; Tyldesley SK; Lohrisch CA
Breast Cancer Res Treat; 2017 Feb; 161(3):549-556. PubMed ID: 28000014
[TBL] [Abstract][Full Text] [Related]
8. Addition of chemotherapy to local therapy in women aged 70 years or older with triple-negative breast cancer: a propensity-matched analysis.
Crozier JA; Pezzi TA; Hodge C; Janeva S; Lesnikoski BA; Samiian L; Devereaux A; Hammond W; Audisio RA; Pezzi CM
Lancet Oncol; 2020 Dec; 21(12):1611-1619. PubMed ID: 33271091
[TBL] [Abstract][Full Text] [Related]
9. De novo metastasis in breast cancer: occurrence and overall survival stratified by molecular subtype.
Press DJ; Miller ME; Liederbach E; Yao K; Huo D
Clin Exp Metastasis; 2017 Dec; 34(8):457-465. PubMed ID: 29288366
[TBL] [Abstract][Full Text] [Related]
10. De Novo Versus Recurrent HER2-Positive Metastatic Breast Cancer: Patient Characteristics, Treatment, and Survival from the SystHERs Registry.
Tripathy D; Brufsky A; Cobleigh M; Jahanzeb M; Kaufman PA; Mason G; O'Shaughnessy J; Rugo HS; Swain SM; Yardley DA; Chu L; Li H; Antao V; Hurvitz SA
Oncologist; 2020 Feb; 25(2):e214-e222. PubMed ID: 32043771
[TBL] [Abstract][Full Text] [Related]
11. Occurrence and outcome of de novo metastatic breast cancer by subtype in a large, diverse population.
Tao L; Chu L; Wang LI; Moy L; Brammer M; Song C; Green M; Kurian AW; Gomez SL; Clarke CA
Cancer Causes Control; 2016 Sep; 27(9):1127-38. PubMed ID: 27496200
[TBL] [Abstract][Full Text] [Related]
12. Prognosis of metastatic breast cancer: are there differences between patients with de novo and recurrent metastatic breast cancer?
Lobbezoo DJ; van Kampen RJ; Voogd AC; Dercksen MW; van den Berkmortel F; Smilde TJ; van de Wouw AJ; Peters FP; van Riel JM; Peters NA; de Boer M; Peer PG; Tjan-Heijnen VC
Br J Cancer; 2015 Apr; 112(9):1445-51. PubMed ID: 25880008
[TBL] [Abstract][Full Text] [Related]
13. Survival differences among women with de novo stage IV and relapsed breast cancer.
Dawood S; Broglio K; Ensor J; Hortobagyi GN; Giordano SH
Ann Oncol; 2010 Nov; 21(11):2169-2174. PubMed ID: 20427349
[TBL] [Abstract][Full Text] [Related]
14. Ipatasertib plus paclitaxel versus placebo plus paclitaxel as first-line therapy for metastatic triple-negative breast cancer (LOTUS): a multicentre, randomised, double-blind, placebo-controlled, phase 2 trial.
Kim SB; Dent R; Im SA; Espié M; Blau S; Tan AR; Isakoff SJ; Oliveira M; Saura C; Wongchenko MJ; Kapp AV; Chan WY; Singel SM; Maslyar DJ; Baselga J;
Lancet Oncol; 2017 Oct; 18(10):1360-1372. PubMed ID: 28800861
[TBL] [Abstract][Full Text] [Related]
15. Metastatic pattern discriminates survival benefit of primary surgery for de novo stage IV breast cancer: A real-world observational study.
Wang K; Shi Y; Li ZY; Xiao YL; Li J; Zhang X; Li HY
Eur J Surg Oncol; 2019 Aug; 45(8):1364-1372. PubMed ID: 30837102
[TBL] [Abstract][Full Text] [Related]
16. Locoregional Treatment of the Primary Tumor in Patients With De Novo Stage IV Breast Cancer: A Radiation Oncologist's Perspective.
Choi SH; Kim JW; Choi J; Sohn J; Kim SI; Park S; Park HS; Jeong J; Suh CO; Keum KC; Kim YB; Lee IJ
Clin Breast Cancer; 2018 Apr; 18(2):e167-e178. PubMed ID: 28689012
[TBL] [Abstract][Full Text] [Related]
17. Prognostic value of primary tumor surgery in
Yang YS; Chen YL; Di GH; Jiang YZ; Shao ZM
Transl Cancer Res; 2019 Apr; 8(2):614-625. PubMed ID: 35116794
[TBL] [Abstract][Full Text] [Related]
18. Characteristics and survival of de novo and recurrent metastatic breast cancer in New Zealand.
Lao C; Kuper-Hommel M; Elwood M; Campbell I; Edwards M; Lawrenson R
Breast Cancer; 2021 Mar; 28(2):387-397. PubMed ID: 33044617
[TBL] [Abstract][Full Text] [Related]
19. Factors associated with improved outcomes for metastatic inflammatory breast cancer patients.
Weiss A; Menen RS; Lin HY; Shen Y; Rosso KJ; Shaitelman S; Woodward W; Valero V; Ueno NT; Bedrosian I; Babiera G
Breast Cancer Res Treat; 2018 Jun; 169(3):615-623. PubMed ID: 29460033
[TBL] [Abstract][Full Text] [Related]
20. Primary Tumor Surgery for Patients with De Novo Stage IV Breast Cancer can Decrease Local Symptoms and Improve Quality of Life.
Si Y; Yuan P; Hu N; Wang X; Ju J; Wang J; Ma F; Luo Y; Zhang P; Li Q; Xu B
Ann Surg Oncol; 2020 Apr; 27(4):1025-1033. PubMed ID: 31970572
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]